People buying clones of their dogs is a profitable ongoing consumer business (will persist)

People buying clones of their dogs is a profitable ongoing consumer business (will persist) | we're not taking away the cloning business for consumers. So people love that business. It's a profitable business. We're still supporting that business.

we're not taking away the cloning business for consumers. So people love that business. It's a profitable business. We're still supporting that business.

Beneficiaries (23)

Adverse (6)

{
  "nia": false,
  "qty": "78% cloning efficiency at Viagen (vs. ~2% industry)",
  "url": "https://www.youtube.com/watch?v=Goa6c6Qz__I",
  "mode": "PREDICTION",
  "role": "Guest-CEO",
  "context": "we're not taking away the cloning business for consumers. So people love that business. It's a profitable business. We're still supporting that business.",
  "verbatim": "we're not taking away the cloning business for consumers. So people love that business. It's a profitable business. We're still supporting that business.",
  "conv_cues": "profitable business; we're still supporting",
  "direction": "HAPPEN",
  "timeframe": "Current/ongoing",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "prereq",
      "label": "Nvidia quadrupled chip production output while only doubling human headcount — achieved by deploying AI coding tools (Cursor, Claude Code) a",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -10,
      "source_id": "SEM_012",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "Training runs costing $10 billion for a single model will commence sometime in 2025.",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -9,
      "source_id": "SEM_008",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "2025 will be the definitive year that agentic systems finally hit the mainstream.",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -8,
      "source_id": "SEM_042",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "Recursive self-improvement is already happening now (no longer three years out)",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -7,
      "source_id": "238_009",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "David Sinclair begins partial epigenetic reprogramming trials with Life Biosciences in March 2026.",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -6,
      "source_id": "235_038",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "llm_pre_event",
      "label": "Pet cloning order volumes grow or hold steady (validating 'profitable, ongoing' claim); waitlist remains 5-7 months or longer",
      "source": "Viagen press; Bloomberg / Globe and Mail trade coverage",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.7,
      "expected_date": "2028-09-15",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2030-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "Viagen public statements or trade press report pet cloning waitlist sustained at >=5 months and annual order volume stable or growing vs 2025 baseline"
    },
    {
      "kind": "llm_pre_event",
      "label": "Colossal Biosciences (post Viagen acquisition Nov 2025) maintains pet cloning as continuing operational subsidiary with disclosed revenue continuation",
      "source": "Colossal Biosciences corporate disclosures; Viagen Pets website pricing",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -4,
      "source_id": null,
      "confidence": 0.85,
      "expected_date": "2028-12-31",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2030-12-31",
        "from": "2027-01-01"
      },
      "measurement_criterion": "Colossal annual disclosure or press release confirms Viagen pet cloning subsidiary continues operations with cloning waitlist active and pricing maintained at consumer level (USD 25K-50K)"
    },
    {
      "kind": "llm_pre_event",
      "label": "Competitor entry into commercial pet cloning (e.g., Sinogene Biotechnology US/EU expansion, new entran
... (truncated)